🚀 VC round data is live in beta, check it out!
Celltrion Valuation Multiples
Discover revenue and EBITDA valuation multiples for Celltrion and similar public comparables like Insmed, Hansoh Pharma, Revolution Medicines, Astellas Pharma and more.
Celltrion Overview
About Celltrion
Celltrion Inc is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. The company's operating segments include Biopharmaceuticals and Chemical medicine segment. Its Biopharmaceuticals segment includes products and commodities such as biopharmaceutical drugs and related product-support services. The Chemical Medicine segment covers products and commodities including various chemical medicines. It generates the majority of its revenue from the Biopharmaceuticals segment.
Founded
1991
HQ
Employees
2.9K
Website
Sectors
Financials (LTM)
EV
$32B
Celltrion Financials
Celltrion reported last 12-month revenue of $3B and EBITDA of $1B.
In the same LTM period, Celltrion generated $2B in gross profit, $1B in EBITDA, and $777M in net income.
Revenue (LTM)
Celltrion P&L
In the most recent fiscal year, Celltrion reported revenue of $3B and EBITDA of $1B.
Celltrion expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 36% | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $777M | XXX | $704M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| Net Debt | — | — | $2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Celltrion Stock Performance
Celltrion has current market cap of $31B, and enterprise value of $32B.
Market Cap Evolution
Celltrion's stock price is $140.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32B | $31B | -0.9% | XXX | XXX | XXX | $3.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCelltrion Valuation Multiples
Celltrion trades at 10.6x EV/Revenue multiple, and 28.6x EV/EBITDA.
EV / Revenue (LTM)
Celltrion Financial Valuation Multiples
As of April 22, 2026, Celltrion has market cap of $31B and EV of $32B.
Equity research analysts estimate Celltrion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Celltrion has a P/E ratio of 39.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $31B | XXX | $31B | XXX | XXX | XXX |
| EV (current) | $32B | XXX | $32B | XXX | XXX | XXX |
| EV/Revenue | 10.6x | XXX | 11.4x | XXX | XXX | XXX |
| EV/EBITDA | 28.6x | XXX | 31.3x | XXX | XXX | XXX |
| EV/EBIT | 35.8x | XXX | 40.7x | XXX | XXX | XXX |
| EV/Gross Profit | 17.5x | XXX | 19.2x | XXX | XXX | XXX |
| P/E | 39.5x | XXX | 43.6x | XXX | XXX | XXX |
| EV/FCF | 62.5x | XXX | 68.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Celltrion Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Celltrion Margins & Growth Rates
Celltrion's revenue in the last 12 month grew by 22%.
Celltrion's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.3M for the same period.
Celltrion's rule of 40 is 65% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Celltrion's rule of X is 103% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Celltrion Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | 29% | XXX | 34% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 65% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 103% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Celltrion Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Celltrion | XXX | XXX | XXX | XXX | XXX | XXX |
| Insmed | XXX | XXX | XXX | XXX | XXX | XXX |
| Hansoh Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Revolution Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Astellas Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Daiichi Sankyo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celltrion M&A Activity
Celltrion acquired XXX companies to date.
Last acquisition by Celltrion was on XXXXXXXX, XXXXX. Celltrion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Celltrion
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCelltrion Investment Activity
Celltrion invested in XXX companies to date.
Celltrion made its latest investment on XXXXXXXX, XXXXX. Celltrion invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Celltrion
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Celltrion
| When was Celltrion founded? | Celltrion was founded in 1991. |
| Where is Celltrion headquartered? | Celltrion is headquartered in South Korea. |
| How many employees does Celltrion have? | As of today, Celltrion has over 2K employees. |
| Who is the CEO of Celltrion? | Celltrion's CEO is Sung-Woo Ki. |
| Is Celltrion publicly listed? | Yes, Celltrion is a public company listed on Korea Exchange. |
| What is the stock symbol of Celltrion? | Celltrion trades under 068270 ticker. |
| When did Celltrion go public? | Celltrion went public in 2005. |
| Who are competitors of Celltrion? | Celltrion main competitors are Insmed, Hansoh Pharma, Revolution Medicines, Astellas Pharma. |
| What is the current market cap of Celltrion? | Celltrion's current market cap is $31B. |
| What is the current revenue of Celltrion? | Celltrion's last 12 months revenue is $3B. |
| What is the current revenue growth of Celltrion? | Celltrion revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Celltrion? | Current revenue multiple of Celltrion is 10.6x. |
| Is Celltrion profitable? | Yes, Celltrion is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Celltrion? | Celltrion's last 12 months EBITDA is $1B. |
| What is Celltrion's EBITDA margin? | Celltrion's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Celltrion? | Current EBITDA multiple of Celltrion is 28.6x. |
| What is the current FCF of Celltrion? | Celltrion's last 12 months FCF is $518M. |
| What is Celltrion's FCF margin? | Celltrion's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Celltrion? | Current FCF multiple of Celltrion is 62.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.